Becton, Dickinson and Company (BDX) Lowered to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Becton, Dickinson and Company (NYSE:BDX) from a hold rating to a sell rating in a research report report published on Monday morning.

According to Zacks, “Over the past year, Becton, Dickinson and Company, popularly known as BD, has outperformed the broader industry trends with respect to price performance. The company is steadily progressing with its planned acquisition of medical technology player, C. R. Bard. The $24-billion transaction is slated to be completed in the fourth quarter of fiscal 2017. Post completion, BD expects growth in adjusted earnings starting fiscal 2019. We view the acquisition as a strategic fit which will generate benefits from complementary businesses and geographical expansion. BD's cost-control initiatives are also noteworthy. On the flipside, unfavorable sales performance from the BD Medical segment is a concern in the near term. Performance in the segment was affected by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the U.S.”

BDX has been the subject of several other reports. Stifel Nicolaus reiterated a buy rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Cowen and Company reiterated a buy rating and set a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Barclays PLC reiterated an equal weight rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub upgraded Becton, Dickinson and from a hold rating to a buy rating in a report on Monday, August 14th. Finally, Wells Fargo & Company started coverage on Becton, Dickinson and in a report on Friday, September 22nd. They set an outperform rating and a $225.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $200.93.

Shares of Becton, Dickinson and (NYSE:BDX) opened at 197.14 on Monday. The firm’s 50-day moving average price is $197.20 and its 200 day moving average price is $192.71. The firm has a market capitalization of $44.86 billion, a price-to-earnings ratio of 57.09 and a beta of 1.05. Becton, Dickinson and has a 52 week low of $161.29 and a 52 week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.35 earnings per share. On average, analysts anticipate that Becton, Dickinson and will post $9.46 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2017/10/10/becton-dickinson-and-company-bdx-lowered-to-sell-at-zacks-investment-research.html.

The business also recently announced a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 8th were issued a dividend of $0.73 per share. The ex-dividend date was Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.48%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Ribo Alberto Mas sold 7,463 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $201.41, for a total value of $1,503,122.83. Following the transaction, the executive vice president now owns 29,323 shares in the company, valued at $5,905,945.43. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 75,904 shares of company stock worth $15,242,688. Corporate insiders own 1.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Becton, Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after buying an additional 1,353,780 shares in the last quarter. BlackRock Inc. raised its holdings in Becton, Dickinson and by 2,427.8% during the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. State Street Corp raised its holdings in Becton, Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after buying an additional 342,873 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Becton, Dickinson and by 6.5% during the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Becton, Dickinson and by 4.0% during the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after buying an additional 106,966 shares in the last quarter. Institutional investors own 87.12% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a

According to Zacks, “Over the past year, Becton, Dickinson and Company, popularly known as BD, has outperformed the broader industry trends with respect to price performance. The company is steadily progressing with its planned acquisition of medical technology player, C. R. Bard. The $24-billion transaction is slated to be completed in the fourth quarter of fiscal 2017. Post completion, BD expects growth in adjusted earnings starting fiscal 2019. We view the acquisition as a strategic fit which will generate benefits from complementary businesses and geographical expansion. BD's cost-control initiatives are also noteworthy. On the flipside, unfavorable sales performance from the BD Medical segment is a concern in the near term. Performance in the segment was affected by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the U.S.”

BDX has been the subject of several other reports. Stifel Nicolaus reiterated a buy rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Cowen and Company reiterated a buy rating and set a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Barclays PLC reiterated an equal weight rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub upgraded Becton, Dickinson and from a hold rating to a buy rating in a report on Monday, August 14th. Finally, Wells Fargo & Company started coverage on Becton, Dickinson and in a report on Friday, September 22nd. They set an outperform rating and a $225.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $200.93.

Shares of Becton, Dickinson and (NYSE:BDX) opened at 197.14 on Monday. The firm’s 50-day moving average price is $197.20 and its 200 day moving average price is $192.71. The firm has a market capitalization of $44.86 billion, a price-to-earnings ratio of 57.09 and a beta of 1.05. Becton, Dickinson and has a 52 week low of $161.29 and a 52 week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.35 earnings per share. On average, analysts anticipate that Becton, Dickinson and will post $9.46 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2017/10/10/becton-dickinson-and-company-bdx-lowered-to-sell-at-zacks-investment-research.html.

The business also recently announced a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 8th were issued a dividend of $0.73 per share. The ex-dividend date was Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.48%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Ribo Alberto Mas sold 7,463 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $201.41, for a total value of $1,503,122.83. Following the transaction, the executive vice president now owns 29,323 shares in the company, valued at $5,905,945.43. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 75,904 shares of company stock worth $15,242,688. Corporate insiders own 1.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Becton, Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after buying an additional 1,353,780 shares in the last quarter. BlackRock Inc. raised its holdings in Becton, Dickinson and by 2,427.8% during the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. State Street Corp raised its holdings in Becton, Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after buying an additional 342,873 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Becton, Dickinson and by 6.5% during the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Becton, Dickinson and by 4.0% during the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after buying an additional 106,966 shares in the last quarter. Institutional investors own 87.12% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply